 | ||||||||
| C | ||||||||
| NEWS | ||||||||
Gilead wins speedy FDA review for latest hep C combo Gilead Sciences ($GILD) already reaps billions from its hep C meds Sovaldi and Harvoni, but the company isn't content to sit back with the status quo.
| ||||||||
| See more results | Edit this alert | ||||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
Tidak ada komentar:
Posting Komentar